CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy
Escolar DM, Buyse G, Henricson E, Leshner R, Florence J, Mayhew J, Tesi-Rocha C, Gorni K, Pasquali L, Patel KM, McCarter R, Huang J, Mayhew T, Bertorini T, Carlo J, Connolly AM, Clemens PR, Goemans N, Iannaccone ST, Igarashi M, Nevo Y, Pestronk A, Subramony SH, Vedanarayanan VV, Wessel H, CINRG Group
Annals of neurology · 66 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Center for Research Resources
- Gobierno
- NCRR NIH HHS
- Subvenciones
- National Center for Research Resources (M01-RR-00084); National Center for Research Resources (K-23 RR16281-01); National Center for Research Resources (RR011126); National Center for Research Resources (M01-RR02035-01)
Según 2 financiadores declarados.
Publicación
- Publicado
- 2005-06-27 · Ann Neurol · vol. 58 · número 1 · págs. 151–155
- Editorial
- Wiley
- Citado
- 107 citas · más que el 92% de estudios similares · 3.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 8 trabajos
- Acceso
- De pago
- Áreas de investigación
- Muscle Physiology and Disorders · Muscle metabolism and nutrition · Neurogenetic and Muscular Disorders Research
- Palabras clave
- Duchenne muscular dystrophy, creatine, glutamine, muscle strength, disease-modifying therapy, lung function, drug safety
- MeSH
- muscle, skeletal, humans, muscular dystrophy, duchenne, creatine, glutamine, respiratory function tests, child, child, preschool, male
26 autores
- Diana M. Escolar🇺🇸 · autor de correspondenciaChildren's National; George Washington University
- Gunnar Buyse🇧🇪KU Leuven
- Erik Henricson🇺🇸Children's National; George Washington University
- Robert T. Leshner🇺🇸Virginia Commonwealth University
- Julaine M Florence🇺🇸Washington University in St. Louis
- Jill E. Mayhew🇺🇸Children's Hospital of Richmond at VCU
- Carolina Tesi Rocha🇺🇸Children's National; George Washington University
- Ksenija Gorni🇺🇸Children's National; George Washington University
- Livia Pasquali🇺🇸Children's National; George Washington University
- Kantilal M. Patel🇺🇸Children's National; George Washington University
- Robert McCarter🇺🇸George Washington University
- Jennifer Chunyan Huang🇺🇸Children's National; George Washington University
- Thomas P. Mayhew🇺🇸Virginia Commonwealth University
- Tulio E. Bertorini🇺🇸University of Tennessee Health Science Center; University of Memphis
- Jose Carlo🇵🇷University of Puerto Rico System
- Anne M. Connolly🇺🇸Washington University in St. Louis
- Paula R. Clemens🇺🇸United States Department of Veterans Affairs; University of Pittsburgh; Veterans Health Administration; Children's Hospital of Pittsburgh; VA Pittsburgh Healthcare System
- Nathalie Goemans🇧🇪KU Leuven
- Susan T. Iannaccone🇺🇸Texas Scottish Rite Hospital for Children
- Masanori Igarashi🇺🇸University of Tennessee Health Science Center; University of Memphis
- Yoram Nevo🇮🇱Tel Aviv University
- Alan Pestronk🇺🇸Washington University in St. Louis
- Sub H. Subramony🇺🇸University of Mississippi
- V. Vedanarayanan🇺🇸University of Mississippi
- Henry B. Wessel🇺🇸University of Pittsburgh; Children's Hospital of Pittsburgh
- CINRG Goup
Resumen
El texto original del estudio, en el idioma en que se publicó.
We tested the efficacy and safety of glutamine (0.6 gm/kg/day) and creatine (5 gm/day) in 50 ambulant boys with Duchenne muscular dystrophy in a 6-month, double-blind, placebo-controlled clinical trial. Drug efficacy was tested by measuring muscle strength manually (34 muscle groups) and quantitatively (10 muscle groups). Timed functional tests, functional parameters, and pulmonary function tests were secondary outcome measures. Although there was no statistically significant effect of either therapy based on manual and quantitative measurements of muscle strength, a disease-modifying effect of creatine in older Duchenne muscular dystrophy and creatine and glutamine in younger Duchenne muscular dystrophy cannot be excluded. Creatine and glutamine were well tolerated.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.